You are here

P&T® Journal contents for June 2003


P&T highlights the accomplishments of Dr. Afable, a board member since 2000.
Sonja Sherritze
The FDA's mandate for improved pediatric labeling may lead to a much-needed increase in research for children's therapies.
Marvin M. Goldenberg, PhD, RPh, MS
First things first: antimicrobial agents should have a high degree of activity against the pathogens they are intended to treat.
Burke A. Cunha, MD
Continuing Education Credit
A new drug, omalizumab (Xolair™), appears to be effective in overcoming the difficulties in treating persistent and moderate-to-severe asthma.
Lanny J. Rosenwasser, MD, FAAAAI, David B. Nash, MD, MBA, FACP, and members of the Consensus Panel


Editor-in-Chief David Nash, MD, MBA, discusses the dangers of violating drug-safety protocols in the name of “improved patient care."
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger discusses how to reduce errors when using automated drug-dispensing cabinets.
Matthew Grissinger
Prescription Washington
Stephen Barlas describes the Inspector General's guidelines for PBMs and P&T committees.
Stephen Barlas
Drug News
P&T presents the latest information about approvals, indication changes, industry updates, and news from the FDA
Drug Forecast
The authors review alefacept (Amevive®) for the treatment of psoriasis.
Larisa Chagan, BS, PharmD